MicroLactin® and Equine

Inflammatory Conditions8

8Bello TR, Allen TA. The Use of MicroLactin for Inflammatory Conditions
in EquineVeterinary Practice. Journal of Equine Veterinary Science. 2005;
25(9): 380-382.


A clinical survey was performed of 58 horses that were treated with Duralactin® Equine for a variety of inflammatory conditions. Additional therapies were included as necessary. Improvement was seen in 86% of the cases.

Objective: Objective: Utilize MicroLactin® as a therapeutic for a variety of inflammatory conditions in horses. Conditions that show improvement can be further studied in future placebo-controlled studies.

Materials & Methods

Each horse received 1 scoop of Duralactin Equine (7,000 mg MicroLactin) twice daily with food. Additional therapies were prescribed as necessary. The survey includes a large range of breeds and ages (0.75-36 years). There were 20 mares, 36 geldings, and 2 stallions.


This study did not have a control or placebo consort. Additionally, it is understood that some of the horses conditions were acute and some may have resolved without intervention.

Results & Discussion

Inflammation was reduced in 86% of the cases (44/51). Seven horses were lost to follow-up. The inflammatory conditions included in the survey are listed in Table.1


This clinical survey shows clinical improvement after the supplementation of MicroLactin® in a variety of equine inflammatory conditions. The results can direct future placebo-controlled trials in these and other inflammatory conditions. MicroLactin can affect inflammation throughout the body.

Download the Study PDF